batimastat batimastat batimastat (mnemonic: batty-mustard) (inn/usan, codenamed bb-94) is a drug that was invented by laurie hines of british biotech (now vernalis). it is an antimetastatic drug that belongs to the family of drugs called angiogenesis inhibitors. it acts as a matrix metalloproteinase inhibitor (mmpi) by mimicking natural mmpi peptides. dan lednicer wrote about this compound in book #6 of his organic drug synthesis series. batimastatclinical datapregnancycategory n/a routes ofadministrationinjection into pleural space or abdomenatc codenonelegal statuslegal status never marketed identifiers iupac name (2r,3s)-n4-hydroxy-2-isobutyl-n1--3-succinamide cas number130370-60-4pubchem cid5362422iuphar/bps5145drugbankdb03880chemspider4515033uniibk349f52c9keggd03061chemblchembl279786comptox dashboard (epa)dtxsid20156497 echa infocard100.222.897 chemical and physical dataformulac23h31n3o4s2molar mass477.64 g·mol−13d model (jsmol)interactive image smiles o=c(nc)(nc(=o)((c(=o)no)csc1sccc1)cc(c)c)cc2ccccc2 inchi inchi=1s/c23h31n3o4s2/c1-15(2)12-17(18(22(28)26-30)14-32-20-10-7-11-31-20)21(27)25-19(23(29)24-3)13-16-8-5-4-6-9-16/h4-11,15,17-19,30h,12-14h2,1-3h3,(h,24,29)(h,25,27)(h,26,28)/t17-,18+,19+/m1/s1key:xfilpeoldikjhx-qyzoerebsa-n batimastat was the first mmpi that went into clinical trials. first results of a phase i trial appeared in 1994. the drug reached phase iii but was never marketed; mainly because it couldn't be administered orally (as opposed to the newer and chemically similar mmpi marimastat), and injection into the peritoneum caused peritonitis. it is well-known that other methods of administration include transdermal (skin lotion) as well as rectal suppositories.